What is Proton Therapy

Call Now For More Information

General Questions or
Schedule an Appointment

1-855-528-7248

Current Patients

1-206-306-2800

Physician Line

1-888-987-7782

Clinical Trials

Clinical Trials

Always Researching. Always Advancing.

The medical community continues to conduct research studies on proton therapy. SCCA and other academic medical centers are supporting many ongoing clinical trials to expand our knowledge of the most beneficial applications of proton therapy in treating cancer.

Since proton therapy was approved by the U.S. Food and Drug Administration to treat patients in 1988, the medical community has continued to conduct research on the use of protons in treating different types of cancer through clinical trials. Over the years, many patients have volunteered to take part in these clinical trials to help find improvements in fighting cancer with proton therapy.
With SCCA, our team has made a commitment to participate in clinical trials to further our knowledge of the benefits of proton therapy in many tumor types.

People helping people

Clinical trials are research studies that invite people to participate in the final step in a long process that begins with research in a lab. Each study answers a specific set of scientific questions and explores better ways to prevent, screen for, diagnose or treat a disease. Most treatments used today are the results of past clinical trials. Clinical trials are used even after treatments are approved for use, to help answer additional questions. SCCA Proton Therapy has a registry trial open to all proton therapy patients.

Protocols help us find solutions

For every clinical trial, a protocol, or action plan, is prepared prior to conducting the trial. The protocol describes in detail what will be done in the study, how it will be conducted, and why each part of the study is necessary. Each study has its own rules about who can participate. For instance, some studies need patients with a certain condition, some need healthy people, some need just men or just women, etc.

Your participation can make a difference

Clinical trials are carefully controlled research studies done with patients who volunteer. There are many requirements you must meet to be part of a study. If you qualify, it is up to you whether to take part.
Not all patients are cured with standard therapy, and some standard treatments may have side effects that patients and doctors would prefer to avoid, if possible. So patients may seek help through clinical studies. Patients who participate in studies have the first chance to benefit from treatments that have shown promise in earlier research. They also make an important contribution to medical science by helping doctors learn more about the disease and potential new treatments.

Featured Clinical Trials

Access Breakthrough Treatments. Improve Care to Others.

A critical part of the mission at our partner Seattle Cancer Care Alliance (SCCA) is to bring promising new treatments to patients faster. Patients who participate in clinical studies often have the first chance to benefit from treatment approaches that have shown promise in earlier research.

Proton therapy’s efficacy in treating many types of cancer has been well established, but many questions remain unanswered. Our clinical studies hope to make an important contribution to medical science by helping doctors learn more about how effective proton therapy is in treating cancer when compared with other forms of radiation therapy, and when used in combination with other treatments such as chemotherapy and surgery. We also intend to examine outcomes for patients who receive the higher radiation doses made possible by this precise technology.

Study Principal Investigator Conditions Study ID
Evaluation Tracking Project: A Prospective Chart Review of Patients Treated With Proton Therapy George Laramore, MD Solid Tumors NCT01255748 Learn More
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial L. Christine Fang, MD Breast Cancer NCT02603341 Learn More
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer Smith Apisarnthanarax GI: Esophageal NRG-GI006 Learn More
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL) Jing Zeng, MD Prostate Cancer NCT01617161 Learn More
PARTIQoL (Prostate Advanced Radiaton Technologies Investigating Quality of Life) Registry: A companion to Phase III Randomized Jing Zeng, MD Prostate Cancer PARTIQoL Registry Learn More
Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) Doug Hawkins, MD Childhood: CNS Germ Cell Tumors NCT01602666 Learn More
NRG-BN003 Phase III Trial of Observation Versus Irradiation For a Gross Totally Resected Grade II Meningioma Lia Halasz, MD CNS: Meningioma NCT03180268 Learn More
FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging Jing Zeng, MD Lung Cancer NCT02773238 Learn More
Pediatric Proton Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients treated with Proton Radiation Therapy Ralph Ermoian, MD Childhood Cancers NCT01696721 Learn More
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System Sarah Leary, MD Childhood: Embryonal Tumors NCT00867178 Learn More
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years Doug Hawkins, MD Childhood: Ependymoma NCT01096368 Learn More
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Lia Halasz, MD CNS: Glioblastoma NCT02179086 Learn More
NRG-BN005 A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) For Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas Yolanda Tseng, MD CNS: Glioma NRG-BN005 Learn More
A randomized phase III trial comparing axillary lymph node dissection to axillary radiation In breast cancer patients (CT1-3 N1) who have positive sentinel lymph node disease after NEOADJUVANT chemotherapy Janice Kim, MD Breast Cancer A011202 Learn More
NRG-GI002 A phase II clinical trial platform of sensitization utilizing total neoadjuvant therapy (TNT) in rectal cancer Kit Wong, MD GI: Rectal NRG-GI002 Learn More
Randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma Smith Apisarnthanarax, MD GI: Liver RTOG 1112 Learn More
Phase III intergroup study of temozolomide alone versus RT with concomitant and adjuvant tmz versus RT with adjuvant PCV George Laramore, MD PhD CNS: Glioma RTOG 1071/NCCTG 0577 Learn More
A COG pilot study of intensive induction chemotherapy and 131I-MIBG followed by myeloablative busulfan/melphalan (Bu/Mel) for newly diagnosed high-risk neuroblastoma Doug Hawkins, MD Childhood CNS: Neuroblastoma ANBL09P1 Learn More
Efficacy of carboplatin administered concomitantly with radiation and isotretinoin as a pro-apoptotic agent in other than average risk James Olson, MD Childhood CNS: Medulloblastoma ACNS0332 Learn More
Randomized Phase III Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS) Abha Gupta, MD Childhood CNS: Rhabdomyosarcoma ARST1431 Learn More
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Steven Dubois, MD Childhood CNS: Neuroblastoma ANBL1531 Learn More
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients Nicholas Gottardo, MD Childhood CNS: Medulloblastoma ACNS1422 Learn More

Featured Studies

Study Principal Investigators
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Parker CC, James ND, Brawley CD, et. al. Read Study